Clinical Trial

Study of Serplulimab Plus Chemotherapy as Neoadjuvant Therapy for Limited-stage Small Cell Lung Cancer (LS-SCLC)

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated April 4, 2025 (before its estimated June 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
This investigator-initiated, open-label, prospective Phase II clinical trial, planned to take place across multiple centers in China. We aimed to evaluate the efficacy and safety of surgical resection or chemotherapy following serplulimab plus platinum-containing dual induction therapy for stage II-IIIB (N2) LS-SCLC
Trial Details
NCT Number NCT06911606
Lead Sponsor Guangdong Provincial People's Hospital
Collaborators: Liaoning Cancer Hospital & Institute, Guangzhou No.12 People's Hospital, Second Xiangya Hospital of Central South University
Conditions SCLC, Limited Stage
Enrollment 45 participants
Start Date 2024-05-22
Primary Completion 2026-06-30 (estimated)
Study Completion 2026-06-30 (estimated)
Updated on ClinicalTrials.gov 2025-04-04